Display options
Cite
Batalha S, Ferreira S, Brito C. The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery. Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061305.
Batalha, S., Ferreira, S., & Brito, C. (2021). The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery. Cancers, 13(6), . https://doi.org/10.3390/cancers13061305
Batalha, Sofia, et al. "The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061305
Batalha S, Ferreira S, Brito C. The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery. Cancers (Basel). 2021 Mar 15;13(6). doi: 10.3390/cancers13061305. PMID: 33804027; PMCID: PMC8001103.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Mar 15;13(6). doi: 10.3390/cancers13061305.

The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery.

Cancers

Sofia Batalha, Sofia Ferreira, Catarina Brito

Affiliations

  1. Instituto de Biologia Experimental e Tecnológica (iBET), Apartado 12, 2781-901 Oeiras, Portugal.
  2. Instituto de Tecnologia Química e Biológica António Xavier, University Nova de Lisboa, Avenida da República, 2780-157 Oeiras, Portugal.
  3. Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof Lima Basto, 1099-023 Lisboa, Portugal.

PMID: 33804027 PMCID: PMC8001103 DOI: 10.3390/cancers13061305

Abstract

Breast cancer is the deadliest female malignancy worldwide and, while much is known about phenotype and function of infiltrating immune cells, the same attention has not been paid to the peripheral immune compartment of breast cancer patients. To obtain faster, cheaper, and more precise monitoring of patients' status, it is crucial to define and analyze circulating immune profiles. This review compiles and summarizes the disperse knowledge on the peripheral immune profile of breast cancer patients, how it departs from healthy individuals and how it changes with disease progression. We propose this data to be used as a starting point for validation of clinically relevant biomarkers of disease progression and therapy response, which warrants more thorough investigation in patient cohorts of specific breast cancer subtypes. Relevant clinical findings may also be explored experimentally using advanced 3D cellular models of human cancer-immune system interactions, which are under intensive development. We review the latest findings and discuss the strengths and limitations of such models, as well as the future perspectives. Together, the scientific advancement of peripheral biomarker discovery and cancer-immune crosstalk in breast cancer will be instrumental to uncover molecular mechanisms and putative biomarkers and drug targets in an all-human setting.

Keywords: 3D cell models; MDSC; NK cell; T cell; biomarker; blood; breast cancer; immunosuppression; macrophage; patient data

References

  1. Cancer Lett. 2017 Aug 1;400:243-251 - PubMed
  2. Biosensors (Basel). 2020 Aug 28;10(9): - PubMed
  3. Trends Immunol. 2016 Dec;37(12):855-865 - PubMed
  4. J Biotechnol. 2010 Jul 1;148(1):38-45 - PubMed
  5. Nat Rev Dis Primers. 2019 Sep 23;5(1):66 - PubMed
  6. Clin Cancer Res. 2018 Feb 1;24(3):511-520 - PubMed
  7. Int J Mol Sci. 2019 Dec 11;20(24): - PubMed
  8. Nat Rev Immunol. 2020 Jan;20(1):7-24 - PubMed
  9. Nat Rev Immunol. 2008 Jan;8(1):59-73 - PubMed
  10. Front Immunol. 2018 Mar 08;9:470 - PubMed
  11. Breast Cancer Res Treat. 2012 Dec;136(3):659-71 - PubMed
  12. Oncotarget. 2015 Apr 30;6(12):10284-96 - PubMed
  13. Clin Transl Oncol. 2018 Apr;20(4):476-483 - PubMed
  14. Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9010-5 - PubMed
  15. Clin Cancer Res. 2007 May 1;13(9):2714-21 - PubMed
  16. Br J Cancer. 2003 Oct 20;89(8):1463-72 - PubMed
  17. J Cancer. 2016 Jun 03;7(9):1095-104 - PubMed
  18. N Engl J Med. 2006 Sep 7;355(10):1018-28 - PubMed
  19. Clin Breast Cancer. 2019 Dec;19(6):433-442 - PubMed
  20. Cell Commun Signal. 2017 Jun 21;15(1):23 - PubMed
  21. Med Oncol. 2013 Mar;30(1):432 - PubMed
  22. N Engl J Med. 2018 Nov 29;379(22):2108-2121 - PubMed
  23. Ann Surg Oncol. 2004 Mar;11(3):328-39 - PubMed
  24. Pharm Res. 2013 Jul;30(7):1719-28 - PubMed
  25. Nat Rev Cancer. 2016 Jul;16(7):447-62 - PubMed
  26. Cell Death Dis. 2018 Jan 25;9(2):109 - PubMed
  27. Pharm Res. 2011 Oct;28(10):2379-85 - PubMed
  28. Sci Rep. 2020 Nov 10;10(1):19462 - PubMed
  29. Adv Exp Med Biol. 2020;1219:431-443 - PubMed
  30. Immunobiology. 2010 Sep-Oct;215(9-10):737-47 - PubMed
  31. J Natl Cancer Inst. 1981 Sep;67(3):585-90 - PubMed
  32. Breast Cancer Res Treat. 2012 Jun;133(3):881-8 - PubMed
  33. Genome Med. 2018 Sep 28;10(1):73 - PubMed
  34. Oncotarget. 2017 May 30;8(22):35656-35668 - PubMed
  35. Br Med J. 1957 Apr 6;1(5022):779-86 - PubMed
  36. BMC Cancer. 2018 Oct 1;18(1):938 - PubMed
  37. Cancer Immunol Immunother. 2019 Apr;68(4):577-585 - PubMed
  38. Cells. 2020 Jan 01;9(1): - PubMed
  39. Tumour Biol. 2017 Jun;39(6):1010428317711571 - PubMed
  40. Nat Immunol. 2002 Nov;3(11):991-8 - PubMed
  41. Oncol Rep. 2013 Sep;30(3):1087-93 - PubMed
  42. Aliment Pharmacol Ther. 2006 Oct 15;24(8):1163-77 - PubMed
  43. Clin Cancer Res. 2012 Jun 15;18(12):3478-86 - PubMed
  44. Tumour Biol. 2016 Jul;37(7):9037-43 - PubMed
  45. Ther Adv Med Oncol. 2019 Aug 14;11:1758835919866065 - PubMed
  46. Nat Commun. 2019 Mar 8;10(1):1135 - PubMed
  47. Breast Cancer Res Treat. 2011 Jul;128(2):347-56 - PubMed
  48. Adv Healthc Mater. 2019 Feb;8(4):e1801363 - PubMed
  49. Cancers (Basel). 2019 Dec 12;11(12): - PubMed
  50. Drug Discov Today. 2020 May;25(5):879-890 - PubMed
  51. Onco Targets Ther. 2020 Feb 14;13:1397-1412 - PubMed
  52. J Clin Oncol. 2010 Jan 1;28(1):105-13 - PubMed
  53. PLoS One. 2015 May 20;10(5):e0127028 - PubMed
  54. Front Cell Dev Biol. 2020 Mar 18;8:166 - PubMed
  55. Nat Commun. 2017 Nov 23;8(1):1738 - PubMed
  56. Adv Drug Deliv Rev. 2014 Apr;69-70:103-22 - PubMed
  57. J Clin Invest. 2017 Mar 1;127(3):772-779 - PubMed
  58. Cell Cycle. 2010 Dec 15;9(24):4824-35 - PubMed
  59. Br J Cancer. 2009 Apr 7;100(7):1061-7 - PubMed
  60. Front Immunol. 2018 Sep 11;9:2028 - PubMed
  61. Breast Cancer Res Treat. 2001 Apr;66(3):255-63 - PubMed
  62. Cancer. 1974 Dec;34(6):2014-7 - PubMed
  63. Breast Cancer Res Treat. 1986;7(3):187-92 - PubMed
  64. J Immunol Methods. 2015 Nov;426:1-13 - PubMed
  65. Nat Rev Drug Discov. 2020 Mar;19(3):200-218 - PubMed
  66. Br J Cancer. 1982 Oct;46(4):611-6 - PubMed
  67. J Transl Med. 2016 May 28;14(1):151 - PubMed
  68. Oncol Rep. 2012 Aug;28(2):453-8 - PubMed
  69. J Immunother Cancer. 2016 Oct 18;4:59 - PubMed
  70. PLoS One. 2014 Oct 02;9(9):e108062 - PubMed
  71. J Cell Sci. 2017 Jan 1;130(1):190-202 - PubMed
  72. Oncoimmunology. 2018 Dec 12;8(3):1553477 - PubMed
  73. BMC Cancer. 2018 Apr 3;18(1):366 - PubMed
  74. Trends Immunol. 2018 Sep;39(9):748-763 - PubMed
  75. Br J Cancer. 2014 May 13;110(10):2524-30 - PubMed
  76. Br J Cancer. 2007 Jul 2;97(1):105-11 - PubMed
  77. Breast Cancer. 2017 Jan;24(1):111-120 - PubMed
  78. Br J Cancer. 2020 Mar;122(6):735-744 - PubMed
  79. Onco Targets Ther. 2018 Mar 15;11:1423-1432 - PubMed
  80. Ann Oncol. 2020 May;31(5):569-581 - PubMed
  81. Cancer Res. 2016 Oct 1;76(19):5597-5601 - PubMed
  82. Adv Drug Deliv Rev. 2014 Apr;69-70:42-51 - PubMed
  83. Anticancer Res. 2008 Mar-Apr;28(2A):779-84 - PubMed
  84. Breast Cancer Res Treat. 2012 Feb;132(1):215-23 - PubMed
  85. Clin Cancer Res. 2004 May 15;10(10):3401-9 - PubMed
  86. J Oncol. 2013;2013:835956 - PubMed
  87. Nature. 2019 Feb;566(7745):553-557 - PubMed
  88. Exp Hematol. 2009 Jul;37(7):838-48 - PubMed
  89. J Exp Med. 2016 Oct 17;213(11):2293-2314 - PubMed
  90. J Chemother. 2007 Dec;19(6):716-23 - PubMed
  91. Cancer Immunol Immunother. 2009 Jan;58(1):49-59 - PubMed
  92. J Immunother Cancer. 2019 Nov 27;7(1):325 - PubMed
  93. JAMA Oncol. 2016 Feb;2(2):242-6 - PubMed
  94. Breast Cancer. 2018 May;25(3):284-291 - PubMed
  95. Oncoimmunology. 2015 Nov 10;5(3):e1100791 - PubMed
  96. Lab Chip. 2016 May 21;16(10):1899-908 - PubMed
  97. Eur J Immunol. 2003 Jan;33(1):119-24 - PubMed
  98. Sci Rep. 2019 Sep 17;9(1):13451 - PubMed
  99. NPJ Breast Cancer. 2016;2: - PubMed
  100. EBioMedicine. 2020 Feb;52:102631 - PubMed
  101. Front Bioeng Biotechnol. 2018 May 24;6:66 - PubMed
  102. Trends Biotechnol. 2020 Aug;38(8):857-872 - PubMed
  103. JAMA Netw Open. 2020 Jan 3;3(1):e1919536 - PubMed
  104. Curr Stem Cell Rep. 2016 Jun;2(2):128-139 - PubMed
  105. Cancer Res. 2012 Oct 15;72(20):5188-97 - PubMed
  106. Front Immunol. 2019 Sep 20;10:2155 - PubMed
  107. Oncoimmunology. 2018 Nov 10;8(2):e1542918 - PubMed
  108. Cell Mol Immunol. 2020 Aug;17(8):807-821 - PubMed
  109. Lab Chip. 2014 May 21;14(10):1715-24 - PubMed
  110. Nat Immunol. 2019 Sep;20(9):1220-1230 - PubMed
  111. Clin Cancer Res. 1997 Mar;3(3):483-90 - PubMed
  112. Breast Cancer Res. 2017 Feb 28;19(1):20 - PubMed
  113. Nat Rev Immunol. 2020 Aug;20(8):483-497 - PubMed
  114. Front Immunol. 2018 May 30;9:1209 - PubMed
  115. J Exp Clin Cancer Res. 2020 Aug 17;39(1):161 - PubMed
  116. J Cell Biol. 2020 Sep 7;219(9): - PubMed
  117. Cancer Res. 2007 Dec 15;67(24):11991-9 - PubMed
  118. Ann Oncol. 2020 Dec;31(12):1623-1649 - PubMed
  119. Micromachines (Basel). 2020 Sep 12;11(9): - PubMed
  120. Front Immunol. 2019 Jul 31;10:1767 - PubMed
  121. Breast. 2018 Jun;39:131-138 - PubMed
  122. Clin Dev Immunol. 2010;2010:701657 - PubMed
  123. Science. 2016 Mar 25;351(6280):1463-9 - PubMed
  124. Front Immunol. 2018 Jun 28;9:1474 - PubMed
  125. Front Immunol. 2012 Dec 12;3:375 - PubMed
  126. Br J Cancer. 2015 Jun 30;113(1):150-8 - PubMed
  127. Cancer Res. 2011 May 15;71(10):3505-15 - PubMed
  128. Immunity. 2017 Nov 21;47(5):820-833 - PubMed
  129. World J Gastrointest Oncol. 2015 Aug 15;7(8):111-7 - PubMed
  130. Br J Cancer. 2003 Apr 22;88(8):1301-9 - PubMed
  131. Front Oncol. 2020 Feb 07;10:109 - PubMed
  132. Nat Rev Immunol. 2018 Nov;18(11):671-688 - PubMed
  133. Ann Surg Oncol. 2012 Jan;19(1):217-24 - PubMed
  134. Front Immunol. 2019 May 09;10:1017 - PubMed
  135. Oncotarget. 2017 Mar 21;8(12):20011-20024 - PubMed
  136. Int J Cancer. 2008 Aug 15;123(4):780-6 - PubMed
  137. iScience. 2019 Sep 27;19:388-401 - PubMed
  138. Front Immunol. 2012 Nov 16;3:343 - PubMed
  139. Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447 - PubMed
  140. Oncologist. 2015 May;20(5):474-82 - PubMed
  141. Transl Oncol. 2016 Oct;9(5):384-391 - PubMed
  142. Int J Cancer. 2012 Oct 1;131(7):1611-20 - PubMed
  143. Nat Commun. 2016 May 11;7:11535 - PubMed
  144. Breast Cancer Res. 2011;13(6):R117 - PubMed
  145. Medicine (Baltimore). 2016 Dec;95(49):e5541 - PubMed
  146. Cancer Res. 2020 Jan 15;80(2):263-275 - PubMed
  147. Br J Cancer. 2002 Jul 1;87(1):21-7 - PubMed
  148. Breast Cancer Res Treat. 2005 May;91(2):163-71 - PubMed
  149. Exp Mol Med. 2012 Jan 31;44(1):36-44 - PubMed
  150. PLoS One. 2014 Nov 05;9(11):e111886 - PubMed
  151. Cancer Treat Rev. 2016 May;46:9-19 - PubMed
  152. Cancer Immunol Immunother. 2018 Nov;67(11):1743-1752 - PubMed
  153. J Cell Physiol. 2019 Apr;234(4):3515-3525 - PubMed
  154. Nat Rev Drug Discov. 2013 May;12(5):358-69 - PubMed
  155. Breast Cancer Res. 2016 Jan 26;18(1):10 - PubMed
  156. Sci Rep. 2016 Feb 23;6:21868 - PubMed
  157. Immunol Res. 2012 Apr;52(1-2):139-56 - PubMed
  158. JCI Insight. 2019 Sep 19;4(18): - PubMed
  159. Front Immunol. 2019 Jul 10;10:1593 - PubMed
  160. Breast. 2012 Aug;21(4):468-74 - PubMed
  161. Int J Cancer. 2003 Feb 20;103(5):642-6 - PubMed
  162. Biomedicines. 2018 Feb 11;6(1): - PubMed
  163. Int J Cancer. 1993 Nov 11;55(5):735-8 - PubMed
  164. Int J Cancer. 2007 Oct 1;121(7):1512-9 - PubMed
  165. J Gastrointest Surg. 2017 Nov;21(11):1764-1774 - PubMed
  166. J Clin Invest. 2011 Sep;121(9):3609-22 - PubMed
  167. Cell Rep. 2018 Dec 26;25(13):3884-3893.e3 - PubMed
  168. Nat Biomed Eng. 2020 Apr;4(4):394-406 - PubMed
  169. J Transl Med. 2015 Oct 08;13:324 - PubMed
  170. Cell Tissue Res. 2013 Jun;352(3):671-84 - PubMed
  171. J Immunol. 2013 Mar 1;190(5):2424-36 - PubMed
  172. J Immunol. 2007 Aug 15;179(4):2627-33 - PubMed
  173. Cancer Immunol Immunother. 2004 Jun;53(6):510-8 - PubMed
  174. BMC Cancer. 2009 Aug 22;9:291 - PubMed
  175. Nat Rev Immunol. 2020 May;20(5):279-293 - PubMed
  176. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  177. EPMA J. 2013 Feb 25;4(1):7 - PubMed
  178. Nat Immunol. 2019 Jun;20(6):724-735 - PubMed
  179. Ann Oncol. 2019 Aug 1;30(8):1194-1220 - PubMed
  180. J Transl Med. 2015 Jun 04;13:180 - PubMed
  181. Cancers (Basel). 2018 May 21;10(5): - PubMed
  182. Curr Opin Biotechnol. 2020 Oct;65:242-247 - PubMed
  183. Sci Transl Med. 2012 Nov 7;4(159):159ra147 - PubMed
  184. J Transl Med. 2008 May 16;6:25 - PubMed
  185. Br J Cancer. 2006 Jan 16;94(1):101-7 - PubMed
  186. Biomed Res Int. 2013;2013:279505 - PubMed
  187. Breast Cancer Res Treat. 2018 Apr;168(2):401-411 - PubMed
  188. Clin Transl Oncol. 2019 Jul;21(7):855-863 - PubMed
  189. Br J Cancer. 2007 Nov 5;97(9):1251-9 - PubMed
  190. Cancer Res. 2008 Jul 1;68(13):5405-13 - PubMed
  191. Breast Cancer Res. 2015 Mar 10;17:34 - PubMed
  192. Trends Cancer. 2020 Jul;6(7):605-618 - PubMed
  193. Nat Rev Clin Oncol. 2016 Apr;13(4):228-41 - PubMed
  194. Neoplasia. 2005 Dec;7(12):1112-22 - PubMed
  195. Biol Psychol. 1998 May;48(1):21-35 - PubMed
  196. ACS Nano. 2018 Nov 27;12(11):11041-11061 - PubMed
  197. Breast Cancer Res Treat. 2006 Jul;98(1):17-29 - PubMed
  198. Ann Oncol. 2011 Jun;22(6):1302-1307 - PubMed
  199. Biomed Rep. 2016 Aug;5(2):208-212 - PubMed
  200. Cancer Prev Res (Phila). 2016 Apr;9(4):305-16 - PubMed
  201. Mol Cell Proteomics. 2018 Aug;17(8):1470-1486 - PubMed
  202. Cancer Med. 2019 Feb;8(2):492-500 - PubMed
  203. Nature. 2015 Jul 16;523(7560):313-7 - PubMed
  204. JAMA Oncol. 2019 Apr 11;: - PubMed
  205. Oncotarget. 2016 Jun 7;7(23):34881-9 - PubMed

Publication Types

Grant support